Shire-NPS Pharmaceuticals, Inc. Sustainability Profile
Shire-NPS Pharmaceuticals, Inc., a prominent player in the biopharmaceutical industry, is headquartered in the United States. Founded in 1986, the company has established itself as a leader in developing innovative therapies for rare diseases, particularly in the fields of gastrointestinal and endocrine disorders. With a strong focus on patient-centric solutions, Shire-NPS offers a range of unique products, including treatments for conditions such as short bowel syndrome and hypoparathyroidism. The company’s commitment to research and development has led to significant milestones, including the successful launch of several groundbreaking therapies. Recognised for its expertise in rare disease management, Shire-NPS Pharmaceuticals continues to strengthen its market position, making a meaningful impact on the lives of patients worldwide.
DitchCarbon Score
How does Shire-NPS Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Shire-NPS Pharmaceuticals, Inc.'s score of 75 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Shire-NPS Pharmaceuticals, Inc., headquartered in the US, currently does not have specific carbon emissions data available for recent years. The company is a current subsidiary of Takeda Pharmaceutical Company Limited, which influences its climate commitments and emissions reporting. As part of its corporate family relationship, Shire-NPS Pharmaceuticals inherits climate initiatives and targets from Takeda. This includes participation in the Science Based Targets initiative (SBTi) and the Carbon Disclosure Project (CDP), both of which are managed at the level of Takeda. However, specific reduction targets or achievements for Shire-NPS Pharmaceuticals have not been disclosed. While no absolute emissions figures are provided, the commitment to sustainability and climate action is evident through the cascading of initiatives from Takeda. The company is expected to align with industry standards and best practices in reducing its carbon footprint, although specific metrics and targets remain unspecified at this time.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2015 | 2016 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | 96,000,000 | 00,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 161,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 226,000,000 | 000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 | 0,000,000,000 |
How Carbon Intensive is Shire-NPS Pharmaceuticals, Inc.'s Industry?
How Carbon Intensive is Shire-NPS Pharmaceuticals, Inc.'s Location?
Shire-NPS Pharmaceuticals, Inc.'s Scope 3 Categories Breakdown
Shire-NPS Pharmaceuticals, Inc.'s Scope 3 emissions, which decreased by 29% last year and increased significantly since 2015, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Purchased Goods and Services" being the largest emissions source at 63% of Scope 3 emissions.
Top Scope 3 Categories
Shire-NPS Pharmaceuticals, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Shire-NPS Pharmaceuticals, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
